Prostate cancer
Conditions
Interventions
AR-V7positive:None
AR-V7negative:None
Sponsors
Department of Urology Laboratory, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Patients who are diagnosed with metastatic prostate adenocarcinoma and start to receive standard androgen deprivation therapy included medical castration (luteinizing hormone releasing hormone analogs, LHRH-a) or surgical castration (orchiectomy), combined with medical anti androgen (bicalutamide etc.). The adenocarcinoma is confirmed by Immunohistochemistry (IHC) using formalin-fixed paraffin-embedded (FFPE) needle biopsy. Metastatic disease is confirmed by bone scanning.
Exclusion criteria
Exclusion criteria: 1. Patient who has serious heart, lung, liver or kidney disease; 2. Patient who refuses to accept androgen deprivation therapy; 3. Patient who failed to regulate androgen deprivation therapy under the requirements of doctor; 4. Patient whose serum testosterone does not reach castration level (<50ng/dl); 5. In addition to androgen deprivation therapy, patient who undergoes other anti-tumor therapy, including surgery, chemotherapy or radiation therapy; 6. Patient with a history of transurethral resection of prostate or other cancers; 7. Patient with ECOG performance status score larger than 2.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AR-V7immuno -histochemistry;progress-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| cancer-specific survival;overall survival;PSA response rate; | — |
Countries
China
Contacts
Public ContactYe Zhangqun
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed